GlassScriptPhysician profile
Katharine Nelson
NPI 1497921811
$15,546.40
in general payments reported to CMS, 2019-2025
37 companies · $3,760 in 2025
The $3,760 reported for 2025 was more than what 80% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,283 · 2020: $1,130 · 2021: $2,014 · 2022: $2,557 · 2023: $2,631 · 2024: $2,171 · 2025: $3,760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,528 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,527.60 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,245.88 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $2,936.94 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $2,147.02 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $605.97 | 2020-2025 | Takhzyro, Cuvitru |
| Novartis Pharmaceuticals Corporation | $577.62 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $550.34 | 2019-2025 | Dupixent |
| Ars Pharmaceuticals Operations, INC. | $529.04 | 2025 | Neffy |
| Csl Behring | $517.74 | 2019-2025 | Hizentra, Andembry, Haegarda |
| Teva Pharmaceuticals USA, INC. | $479.41 | 2019-2021 | |
| Amgen INC. | $439.18 | 2022-2025 | Tezspire |
| Pfizer INC. | $335.34 | 2019-2023 | |
| Octapharma USA, INC. | $180.04 | 2019-2024 | Cutaquig |
| Grifols USA, LLC | $178.58 | 2020-2025 | Xembify |
| Genentech USA, INC. | $160.52 | 2019-2024 | Xolair |
| Pharming Healthcare, INC. | $152.45 | 2024-2025 | Ruconest |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.96 | 2019-2023 | Stiolto Respimat |
| Biocryst US Sales Co., LLC | $130.49 | 2022-2025 | Orladeyo |
| Allergan, INC. | $125.00 | 2020 | |
| Galderma Laboratories, L.P. | $123.65 | 2025 | Nemluvio |
| Lilly USA, LLC | $123.08 | 2025 | Ebglyss |
| Kaleo, INC. | $117.63 | 2019-2024 | Auvi-Q |
| Incyte Corporation | $84.47 | 2021-2022 | |
| Optinose US, INC. | $83.66 | 2019-2024 | |
| Medtronic USA, INC. | $83.27 | 2019 | |
| Sanofi-Aventis U.S. LLC | $71.45 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $69.61 | 2025 | Zoryve |
| Hikma Pharmaceuticals USA | $66.17 | 2023-2024 | Ryaltris |
| Alk-Abello, INC | $62.98 | 2020-2022 | |
| Shire North American Group INC | $40.93 | 2019 | |
| Blueprint Medicines Corporation | $38.52 | 2025 | Ayvakit |
| Aerin Medical INC. | $33.69 | 2022 | |
| Covis Pharma Gmbh | $27.74 | 2019 | |
| Hospira, INC. | $27.38 | 2022 | |
| Uswm, LLC | $21.00 | 2021 | |
| Circassia INC. | $19.61 | 2019 | |
| Horizon Therapeutics Plc | $12.97 | 2021 | |
| Organon LLC | $9.07 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katharine Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.